The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway

Cancer patients who initially benefit from Erlotinib, a drug targeting EGFR path, eventually develop resistance to the drug. The underlying mechanism is largely unknown. This study investigated the role of ARL4C in Erlotinib resistance development of NSCLC. qRT-PCR and Western blotting were performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jinrong, Chen, Zeng, Yu, Zongyang, Huang, Tao, Hu, Dan, Su, Ying, He, Zhiyong, Zou, Changyan, Zhang, Lurong, Lin, Xiandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657464/
https://www.ncbi.nlm.nih.gov/pubmed/33194732
http://dx.doi.org/10.3389/fonc.2020.585292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657464/
https://www.ncbi.nlm.nih.gov/pubmed/33194732
http://dx.doi.org/10.3389/fonc.2020.585292

Ejemplares similares